Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > News > Cancer drugs, costs and clinical benefits are not aligned
  • News

Cancer drugs, costs and clinical benefits are not aligned

  • 1 June 2020
  • Elena Riboldi
Cancer drugs, costs and clinical benefits are not aligned
Total
0
Shares
0
0
0
0
0

According to an international study just published in Lancet Oncology,  the cost of new cancer drugs is not associated to the clinical value of the therapy: “In the USA and European countries, prices of cancer drugs should be better aligned with their clinical importance, such as by prioritising drugs with low or uncertain benefit for price negotiations, to improve access to beneficial drugs and enable finite resources to be used for treatments that offer patients improved outcomes and optimal value” write Kerstin Noëlle Vokinger, professor for health law at the University of Zurich, and colleagues.

Vokinger’s group focused on 65 drugs approved in the last decade for the treatment of solid tumours or haematological malignancies. Monthly treatment costs for each drug were calculated separately for the USA and for four European countries (England, France, Germany, Switzerland). Cancer drug costs were more than double in the USA compared to Europe. This difference is mainly due to the fact that, by contrast with the USA, European countries have policies that allow national authorities to negotiate drug prices with manufacturers.

Strikingly, no significant associations between monthly drug treatment costs and clinical benefit was observed: for a given cancer type, a drug with lower clinical benefit score may have similar or even higher monthly costs compared to another drug with a higher score.

The clinical value of cancer therapies was evaluated using two frameworks developed by the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). The two tools have moderate concordance, although they were originally developed for different purposes: the ASCO Value Framework (ASCO-VF) was designed to help shared decision making on the most beneficial drug for an individual patient; the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) was designed to identify cancer therapies that should be made rapidly available in every EU country. “In both the USA and in European countries, pricing for cancer drugs is complicated by the fact that many newly approved cancer drugs have weak or uncertain evidence about their clinical value, often because they are approved on the basis of surrogate endpoints” the author explain. Value frameworks can help identify therapies providing high clinical benefit and are useful tools for policy makers determined to to promote the affordability of new drugs.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • ASCO
  • cancer drugs
  • ESMO
  • Magnitude of Clinical Benefit Scale
  • price
  • Value framework
Elena Riboldi

Previous Article
  • Voices

EORTC pushes for the State of Science in Care

  • 30 May 2020
  • Denis Lacombe
View Post
Next Article
  • Articles
  • Medicine

CCC-19 and TERAVOLT studies show strength and limits of research on cancer and COVID-19

  • 1 June 2020
  • Daniela Ovadia
View Post
You May Also Like
View Post
  • News

Study highlights need to reanalyse genomics and genetics of metastatic tumours

  • Janet Fricker
  • 27 January 2023
View Post
  • News

Current cervical cancer screening paradigm fails older women

  • Janet Fricker
  • 26 January 2023
View Post
  • News

Call-to-arms for Europe to provide essential paediatric anti-cancer medicines

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Exercise-stimulated myokine production can extend survival in advanced prostate cancer

  • Janet Fricker
  • 9 January 2023
View Post
  • News

Five San Antonio take-aways to improve care of breast cancer patients

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Repurposed drug combination reduces risk of recurrence following surgery for colorectal cancer

  • Janet Fricker
  • 16 December 2022
View Post
  • News

Aerobic activity to outcompete metastasis 

  • Janet Fricker
  • 2 December 2022
View Post
  • News

Ending cancer inequalities: European summit showcases new tools to inform policy

  • Anna Wagstaff
  • 30 November 2022

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Study highlights need to reanalyse genomics and genetics of metastatic tumours
    • 27 January 2023
  • Current cervical cancer screening paradigm fails older women
    • 26 January 2023
  • Call-to-arms for Europe to provide essential paediatric anti-cancer medicines
    • 9 January 2023
  • Exercise-stimulated myokine production can extend survival in advanced prostate cancer
    • 9 January 2023
  • Five San Antonio take-aways to improve care of breast cancer patients
    • 16 December 2022
Article
  • The cancer patients still struggling to access drugs in the wake of anti-corruption reforms
    • 27 January 2023
  • Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access
    • 26 January 2023
  • Cervical cancer elimination efforts boosted by simpler ways to identify and treat pre-cancerous lesions
    • 12 January 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • Hansjörg Senn of St Gallen: A practice-changing career
    • 3 February 2023
  • AI in Genomics and Reporting for Clinical Practice
    • 26 January 2023
  • Telemedicine in Cancer Care: Monitoring, Follow-Up,Tele-Rehabilitation, Palliative and Supportive Care
    • 23 January 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is funded by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.